Chemotherapy for localized, high-risk prostate cancer.
Chemotherapy for prostate cancer currently has an established role in the treatment of hormone refractory prostate cancer. In addition, there is strong evidence that androgen ablation in addition to radiotherapy provides a benefit above and beyond radiotherapy alone in patients with a poor prognosis, perhaps because of an effect of androgen ablation on subclinical distant disease. There are currently several clinical trials that are investigating whether the addition of chemotherapy with known efficacy in the hormone-refractory setting can provide a survival advantage when used adjunctly. The role of chemotherapy in the nonmetastatic prostate, hormone-naïve prostate cancer patient will be discussed.
Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI 48109-0010, USA.
Samir
S
Narayan
David C
DC
Smith
Howard M
HM
Sandler
D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology*; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen